Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


European Union

Government will 'review its position' on no-deal Brexit drug stockpiles

Following the extension to Article 50, the government says it is “considering the impact on our EU exit preparations”.

The government has said it will “review its position” on drug stockpiles held in case of a no-deal Brexit after the UK agreed an extension to its date for leaving the EU.

Pharmaceutical companies said they wanted clarity on what will happen to no-deal Brexit medicine stockpiles that have been built up following the agreement that the UK may now not leave the EU until October 2019, more than six months after the original Brexit date of 29 March 2019.

Drugs manufacturers were asked to develop six-week stockpiles for a number of drugs to ensure a continuous supply in the event of a no-deal Brexit.

Following an EU leaders summit on 10 April 2019, an agreement has been put in place with the EU that could extend the Article 50 process so that the UK remains in the EU until 31 October 2019.

Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry, said his members wanted to know what happens next. 

“Companies are doing everything they can to protect the supply of medicines whatever the Brexit outcome. As part of this they have increased stocks of medicines in line with government guidance.

“With the extension of Article 50, we will work with government to consider how best to prepare and review whether current plans for a no-deal Brexit are still appropriate.”

Warwick Smith, director general of the British Generic Manufacturers Association, said: “We will work with the government and other stakeholders carefully to review the revised position. In the meantime, current guidance will remain in place.”

Meanwhile, Niall Dickson, co-chair of the Brexit Health Alliance — which represents the NHS Confederation, the Academy of Medical Royal Colleges, and many other healthcare bodies — said the end of the immediate threat of a no-deal Brexit was “a relief”.

“But of course the extension leaves that as one potential outcome, which means everyone involved in healthcare must continue to prepare for this possibility and keep contingency plans in place,” he said.

“We are now in a ‘phoney war’ and the risk is complacency — the system needs to assume we could crash out and do everything we can to make sure patients are protected if that happens.”

A spokesperson for the Department of Health and Social Care said: “Leaving the EU with a deal remains the government’s priority.

“We are considering the impact on our EU exit preparations and are working closely with our stakeholders to review our position.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206435

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.